APEA 3P Exam Study Guide 2026 | Verified
Questions & Answers for Advanced Practice
Nursing Success
APEA 3P EXAM STUDY GUIDE 2026
Verified Questions & Answers for Advanced Practice Nursing Success
DOCUMENT OVERVIEW
• Comprehensive, evidence-based questions systematically covering
pharmacology, pathophysiology, clinical assessment, diagnostics, and management
of complex patient scenarios encountered in advanced practice nursing
• Strategic study approach - review questions daily, use EXPERT RATIONALE to
deepen pharmacologic and pathophysiologic knowledge, focus on clinical
reasoning patterns, and test yourself before reviewing answers for maximum
retention and exam preparedness
QUESTIONS : COMPLETE APEA 3P EXAM PREPARATION
1. A 58-year-old male patient with hypertension presents with a blood
pressure of 165/95 mmHg. He is currently not on any antihypertensive
medications. Which first-line antihypertensive agent would be most
appropriate for this patient with no other comorbidities?
A) Immediate-release nifedipine
B) Clonidine
C) Lisinopril
D) Hydralazine
E) Spironolactone
C) Lisinopril
,EXPERT RATIONALE: ACE inhibitors like lisinopril are recommended as first-line
agents for hypertension management in patients without specific contraindications.
They are effective, have cardioprotective properties, and are well-tolerated.
Immediate-release nifedipine is reserved for hypertensive emergencies, clonidine
causes significant side effects and is a second-line agent, hydralazine is used in
pregnancy or resistant hypertension, and spironolactone is a potassium-sparing
diuretic used for resistant hypertension or specific conditions like heart failure.
2. A patient with type 2 diabetes mellitus is started on metformin therapy.
Which of the following represents the PRIMARY mechanism of action of
metformin?
A) Stimulates insulin secretion from pancreatic beta cells
B) Decreases hepatic glucose production and increases peripheral glucose uptake
C) Inhibits alpha-glucosidase enzymes in the small intestine
D) Activates peroxisome proliferator-activated receptors
E) Increases GLP-1 receptor signaling
B) Decreases hepatic glucose production and increases peripheral glucose
uptake
EXPERT RATIONALE: Metformin's primary mechanism involves suppressing
hepatic gluconeogenesis and enhancing insulin sensitivity in peripheral tissues,
leading to increased glucose utilization. It does not stimulate insulin secretion,
which distinguishes it from sulfonylureas. Alpha-glucosidase inhibition is the
mechanism of acarbose, PPAR activation is how thiazolidinediones work, and GLP-1
agonists activate incretin pathways—none of these are metformin's primary action.
3. A 72-year-old female with a history of atrial fibrillation is on warfarin
therapy. Her INR is 8.2 (therapeutic range 2-3). She is asymptomatic with no
bleeding. What is the most appropriate management?
A) Administer fresh frozen plasma immediately
,B) Administer vitamin K and hold warfarin
C) Continue warfarin at the same dose and recheck INR in 3 days
D) Administer protamine sulfate
E) Administer vitamin K only
B) Administer vitamin K and hold warfarin
EXPERT RATIONALE: An INR of 8.2 in an asymptomatic patient without bleeding
requires correction with vitamin K (phytonadione) and warfarin discontinuation.
Fresh frozen plasma and protamine sulfate are reserved for life-threatening
bleeding. Continuing warfarin increases bleeding risk significantly. Vitamin K alone
may take 24-48 hours to work, so holding warfarin is necessary. The combination
approach balances bleeding risk mitigation with appropriate anticoagulation
management.
4. A 45-year-old patient develops angioedema while taking an ACE inhibitor
for hypertension. Which alternative antihypertensive agent would be
CONTRAINDICATED due to cross-reactivity risk?
A) Amlodipine
B) Hydralazine
C) Losartan
D) Atenolol
E) Chlorthalidone
C) Losartan
EXPERT RATIONALE: Angiotensin II receptor blockers (ARBs) like losartan carry a
25-30% cross-reactivity risk with ACE inhibitor-induced angioedema due to similar
mechanisms affecting bradykinin metabolism. Calcium channel blockers
(amlodipine), vasodilators (hydralazine), beta-blockers (atenolol), and thiazide
diuretics (chlorthalidone) do not share this cross-reactivity risk and are safe
alternatives.
, 5. A 52-year-old male with newly diagnosed type 2 diabetes and BMI of 32
kg/m² presents for medication management. Which agent would provide
additional cardiovascular and weight loss benefits beyond glycemic control?
A) Insulin glargine
B) Pioglitazone
C) Empagliflozin
D) Saxagliptin
E) Acarbose
C) Empagliflozin
EXPERT RATIONALE: SGLT2 inhibitors like empagliflozin have demonstrated
cardiovascular protective effects in multiple trials, reduce hospitalizations for heart
failure, promote weight loss through glucosuria, and lower blood pressure. Insulin
glargine causes weight gain, pioglitazone increases fluid retention and weight,
saxagliptin (DPP-4 inhibitor) provides modest weight neutral effects with limited
cardiovascular benefit, and acarbose causes GI side effects and minimal weight
loss.
6. A patient with chronic kidney disease stage 3B (eGFR 35-44 mL/min/1.73m²)
is prescribed a new antifungal medication. Which agent requires the MOST
significant dose adjustment due to renal impairment?
A) Fluconazole
B) Itraconazole
C) Amphotericin B
D) Voriconazole
E) Posaconazole
A) Fluconazole
Questions & Answers for Advanced Practice
Nursing Success
APEA 3P EXAM STUDY GUIDE 2026
Verified Questions & Answers for Advanced Practice Nursing Success
DOCUMENT OVERVIEW
• Comprehensive, evidence-based questions systematically covering
pharmacology, pathophysiology, clinical assessment, diagnostics, and management
of complex patient scenarios encountered in advanced practice nursing
• Strategic study approach - review questions daily, use EXPERT RATIONALE to
deepen pharmacologic and pathophysiologic knowledge, focus on clinical
reasoning patterns, and test yourself before reviewing answers for maximum
retention and exam preparedness
QUESTIONS : COMPLETE APEA 3P EXAM PREPARATION
1. A 58-year-old male patient with hypertension presents with a blood
pressure of 165/95 mmHg. He is currently not on any antihypertensive
medications. Which first-line antihypertensive agent would be most
appropriate for this patient with no other comorbidities?
A) Immediate-release nifedipine
B) Clonidine
C) Lisinopril
D) Hydralazine
E) Spironolactone
C) Lisinopril
,EXPERT RATIONALE: ACE inhibitors like lisinopril are recommended as first-line
agents for hypertension management in patients without specific contraindications.
They are effective, have cardioprotective properties, and are well-tolerated.
Immediate-release nifedipine is reserved for hypertensive emergencies, clonidine
causes significant side effects and is a second-line agent, hydralazine is used in
pregnancy or resistant hypertension, and spironolactone is a potassium-sparing
diuretic used for resistant hypertension or specific conditions like heart failure.
2. A patient with type 2 diabetes mellitus is started on metformin therapy.
Which of the following represents the PRIMARY mechanism of action of
metformin?
A) Stimulates insulin secretion from pancreatic beta cells
B) Decreases hepatic glucose production and increases peripheral glucose uptake
C) Inhibits alpha-glucosidase enzymes in the small intestine
D) Activates peroxisome proliferator-activated receptors
E) Increases GLP-1 receptor signaling
B) Decreases hepatic glucose production and increases peripheral glucose
uptake
EXPERT RATIONALE: Metformin's primary mechanism involves suppressing
hepatic gluconeogenesis and enhancing insulin sensitivity in peripheral tissues,
leading to increased glucose utilization. It does not stimulate insulin secretion,
which distinguishes it from sulfonylureas. Alpha-glucosidase inhibition is the
mechanism of acarbose, PPAR activation is how thiazolidinediones work, and GLP-1
agonists activate incretin pathways—none of these are metformin's primary action.
3. A 72-year-old female with a history of atrial fibrillation is on warfarin
therapy. Her INR is 8.2 (therapeutic range 2-3). She is asymptomatic with no
bleeding. What is the most appropriate management?
A) Administer fresh frozen plasma immediately
,B) Administer vitamin K and hold warfarin
C) Continue warfarin at the same dose and recheck INR in 3 days
D) Administer protamine sulfate
E) Administer vitamin K only
B) Administer vitamin K and hold warfarin
EXPERT RATIONALE: An INR of 8.2 in an asymptomatic patient without bleeding
requires correction with vitamin K (phytonadione) and warfarin discontinuation.
Fresh frozen plasma and protamine sulfate are reserved for life-threatening
bleeding. Continuing warfarin increases bleeding risk significantly. Vitamin K alone
may take 24-48 hours to work, so holding warfarin is necessary. The combination
approach balances bleeding risk mitigation with appropriate anticoagulation
management.
4. A 45-year-old patient develops angioedema while taking an ACE inhibitor
for hypertension. Which alternative antihypertensive agent would be
CONTRAINDICATED due to cross-reactivity risk?
A) Amlodipine
B) Hydralazine
C) Losartan
D) Atenolol
E) Chlorthalidone
C) Losartan
EXPERT RATIONALE: Angiotensin II receptor blockers (ARBs) like losartan carry a
25-30% cross-reactivity risk with ACE inhibitor-induced angioedema due to similar
mechanisms affecting bradykinin metabolism. Calcium channel blockers
(amlodipine), vasodilators (hydralazine), beta-blockers (atenolol), and thiazide
diuretics (chlorthalidone) do not share this cross-reactivity risk and are safe
alternatives.
, 5. A 52-year-old male with newly diagnosed type 2 diabetes and BMI of 32
kg/m² presents for medication management. Which agent would provide
additional cardiovascular and weight loss benefits beyond glycemic control?
A) Insulin glargine
B) Pioglitazone
C) Empagliflozin
D) Saxagliptin
E) Acarbose
C) Empagliflozin
EXPERT RATIONALE: SGLT2 inhibitors like empagliflozin have demonstrated
cardiovascular protective effects in multiple trials, reduce hospitalizations for heart
failure, promote weight loss through glucosuria, and lower blood pressure. Insulin
glargine causes weight gain, pioglitazone increases fluid retention and weight,
saxagliptin (DPP-4 inhibitor) provides modest weight neutral effects with limited
cardiovascular benefit, and acarbose causes GI side effects and minimal weight
loss.
6. A patient with chronic kidney disease stage 3B (eGFR 35-44 mL/min/1.73m²)
is prescribed a new antifungal medication. Which agent requires the MOST
significant dose adjustment due to renal impairment?
A) Fluconazole
B) Itraconazole
C) Amphotericin B
D) Voriconazole
E) Posaconazole
A) Fluconazole
